MIRANSERTIB
Miransertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against RAC-gamma serine/threonine-protein kinase, RAC-beta serine/threonine-protein kinase, and RAC-alpha serine/threonine-protein kinase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Proteus syndrome | D016715 | Orphanet_744 | Q87.3 | 1 | 1 | — | — | 1 | 3 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | — | — | — | — | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | — | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Growth disorders | D006130 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MIRANSERTIB |
| INN | miransertib |
| Description | Miransertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against RAC-gamma serine/threonine-protein kinase, RAC-beta serine/threonine-protein kinase, and RAC-alpha serine/threonine-protein kinase. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1ncccc1-c1nc2ccc(-c3ccccc3)nc2n1-c1ccc(C2(N)CCC2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 101409-76-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297188 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | T1DQI1B52Y (ChemIDplus, GSRS) |
Target
Agency Approved
AKT3
AKT3
AKT2
AKT2
AKT1
AKT1
Organism
Homo sapiens
Gene name
AKT3
Gene synonyms
PKBG
NCBI Gene ID
Protein name
RAC-gamma serine/threonine-protein kinase
Protein synonyms
PKB gamma, Protein kinase Akt-3, Protein kinase B gamma, RAC-gamma serine/threonine protein kinase, RAC-PK-gamma, STK-2, v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma)
Uniprot ID
Mouse ortholog
Akt3 (23797)
RAC-gamma serine/threonine-protein kinase (Q9WUA6)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 316 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use